PDCD1 and non-small cell lung carcinoma: Approximately 3.8–29.4% of cancer patients and 13.8–37% of advanced non-small cell lung cancer (NSCLC) patients under anti-programmed cell death 1/ programmed death ligand 1 (PD-1/PD-L1) inhibitors, reported HPD [6].